Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy has failed to beat placebo in a phase 2 clinical trial. Functional motor ability scores in the SRP-9001 arm were statistically no ...
Zacks Investment Research on MSN
KROS stock: What to know about Rinvatercept in DMD
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular ...
Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early ...
Pfizer is getting back to work on a late-stage test for its Duchenne muscular dystrophy (DMD) gene therapy. The decision comes several months after a patient death in a phase 1 trial drew a clinical ...
Early screening for Duchenne muscular dystrophy can help you get early treatments and referrals for your child to help prevent further loss of muscle tissue. Duchenne muscular dystrophy (DMD) is a ...
Muscular dystrophy is a group of diseases that make muscles weaker and less flexible over time. It is caused by a problem in the genes that control how the body keeps muscles healthy. Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results